Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 7707 results

  1. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969

      Status ...

    Technology appraisal guidance
    Topic selection

  2. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  3. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development

  5. Olorofim for treating invasive fungal infections in people 16 years and over TS ID 11983

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

    Diagnostics guidance
    Published
    11 November 2015
    View recommendations

    Sections for DG19

  8. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer

    Diagnostics guidance
    Published
    9 May 2024
    View recommendations

    Sections for DG58

  9. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cor-Knot for tying suture knots in valve surgery

      Status ...

    Medical technologies guidance
    Topic selection

  14. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

      Status ...

    Medical technologies guidance
    Topic selection

  15. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

      Status ...

    Medical technologies guidance
    Topic selection